Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 1027-1033

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Nakamura, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cardiometabolic disease; Oxidative stress; PEDF

Indexed keywords

ANGIOTENSIN II; LEPTIN; PIGMENT EPITHELIUM DERIVED FACTOR; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DOSE RESPONSE; GROWTH INHIBITION; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; MITOSIS INHIBITION; NERVE CELL DIFFERENTIATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; ANIMAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY; RAT; RISK FACTOR;

ANGIOPLASTY, BALLOON; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EYE PROTEINS; HUMANS; NERVE GROWTH FACTORS; OXIDATIVE STRESS; RATS; RISK FACTORS; SERPINS;

EID: 65549160061     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787581940     Document Type: Review

References (72)

1. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med 1999; 340: 115-26.
2. Introna M, Mantovani A. Early activation signals in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 423-8.
3. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
4. Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med 2006; 6: 501-14.
5. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8: 1138-43.
6. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172-8.
7. Yamagishi S, Ueda S, Matsui T, Nakamura K, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17: 983-96.
8. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 2005; 5: 309-22.
9. Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12: 1549-54.
10. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
11. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-7.
12. Tombran-Tink J, Chader CG, Johnson LV. PEDF: Pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-4.
13. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4: 628-36.
14. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu HJ, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
15. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-9.
16. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2002; 50: 2641-5.
17. Ogata N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001; 132: 378-82.
18. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400.
19. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003; 65: 186-90.
20. Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, et al. Pigment epithelium-derived factor inhibits TNFalpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497-506.
21. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel antioxidative mechanism of PEDF. Cell Tissue Res 2005; 320: 437-45.
22. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, et al. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 2006; 71: 222-6.
23. Yamagishi S, Matsui T, Nakamura K, Inagaki Y, Takenaka K, Jinnouchi Y, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20.
24. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580: 2788-96.
25. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006; 72: 86-90.
26. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Inoue H, et al. Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sci 2006; 79: 1981-7.
27. Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Makino T, Norisugi O, et al. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006; 38: 546-8.
28. Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue H. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2. Med Chem 2006; 2: 265-9.
29. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, et al. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007; 39: 92-7.
30. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 2007; 39: 233-5.
31. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y, et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007; 170: 2159-70.
32. Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Protein Pept Lett 2007; 14: 615-7.
33. Jinnouchi Y, Yamagishi S, Matsui T, Takenaka K, Yoshida Y, Nakamura K, et al. Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 2007; 1167: 92-100.
34. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Jinnouchi Y, Yoshida Y, et al. Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis 2008; 197: 25-33.
35. Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14: 832-5.
36. Yamagishi S, Abe R, Jinnouchi Y, Matsui T, Imaizumi T, Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J Int Med Res 2007; 35: 896-9.
37. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40: 620-5.
38. Yamagishi S, Matsui T, Nakamura K, Takenaka K. Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats. Clin Exp Med 2008; [Epub ahead of print].
39. Yamagishi S, Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H. Pigment epithelium-derived factor prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009.
40. Manitovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
41. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60: 1185-95.
42. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor-alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type. J Exp Med 1992; 177: 1277-86.
43. Nawroth PP, Stern DM. Modulation of endothelial cells hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
44. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 2004; 286: H1001-7.
45. Frey RS, Rahman A, Kefe, JC, Minshall RD, Malik AB. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ Res 2002; 90: 1012-9.
46. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-a-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15: 2423-32.
47. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Cir Res 2000; 86: 494-501.
48. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Cir Res 1999; 85: 753-66.
49. Yamagishi S, Matsui T, Inoue H. Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp Clin Res 2005; 31: 227-32.
50. Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005; 31: 215-9.
51. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-9.
52. Sierra-Honigmann M, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science 1999; 281: 1683-6.
53. Yamagishi S, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoaatractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-100.
54. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-7.
55. Baba H, Yonemitsu Y, Nakano T, Onimaru M, Miyazaki M, Ikeda Y, et al. Cytoplasmic expression aand extracelluar deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic paques. Arterioscler Thromb Vasc Biol 2005; 25: 1938-44.
56. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001; 91: 149-66.
57. Levizki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005; 65: 581-6.
58. Ho TC, Yang YC, Chen SL, Kuo PC, Sytwu HK, Cheng HC, et al. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferators-activated receptor gamma. Mol Immunol 2008; 45: 898-909.
59. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006; 47: 3912-8.
60. Monaco C, Andreakos E, Kiiriakidis S, Feldmann M, Paleolog E. T-cell-mediated signaling in imuune, inflammatory and angiogenic process: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004; 3: 35-42.
61. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008; 263: 489-99.
62. Rondina MT, Muhlestein JB. Early initiation of statin therapy in acute coronary syndromes: a review of the evidence. J Interv Cardiol 2005; 18: 55-63.
63. Nair P, Roguin A. Stains and the acute coronary syndrome: 'the early bird catches the worm'. Int J Clin Prac 2006; 60: 716-27.
64. Ferguson JJ. The role of oral antiplatelet agents in atherothrombotic disease. Am J Cardiovasc Drugs 2006; 6: 149-57.
65. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004; 25: 1197-207.
66. Yamagishi S, Matsui T, Nakamura K, Takenaka K. Pigment epithelium-derived factor (PEDF) inhibits collagen-induced platelet activation by reducing intraplatelet nitrotyrosine levels. Int J Cardiol (in press).
67. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008; 14: 987-9.
68. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 2447-50.
69. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Inoue H. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 52-6.
70. Kratchmarova I, Kalume DE, Blagoev B, Scherer PE, Podtelejnikov AV, Molina H, et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics 2002; 1: 213-22.
71. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
72. Motomiya Y, Yamagishi S, Adachi H, Abe A. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem 2006; 52: 1970-1.